• / Free eNewsletters & Magazine
  • / My Account
Home>Authors>Damien Conover

Damien Conover

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  5. Research
  1. Friday Five: Banks Start Earnings Season Without a Bang

    Plus, strong results push Netflix shares further out of reach this week, while Google stock gets more interesting as European regulators make a move.

  2. J&J Faces Headwinds in 2015

    The pharmaceutical giant turned in an in line fourth-quarter, but new competition and a strong dollar will slow growth in 2015, writes Morningstar’s Damien Conover .

  3. Prescribe to Pharma for Emerging-Markets Growth

    Many developed-country health-care firms have deep roots in emerging markets and can be a good way to gain exposure, says Morningstar's Damien Conover .

  4. Pfizer-Astra Deal Will Get Done

    Cost-cutting, tax opportunities, and oncology synergies are motivating factors for Pfizer, and the firms will likely agree to merge, says Morningstar's Damien Conover .

  5. J&J's Strong 2Q Led by Pharmaceuticals

    Unexpectedly robust sales of hepatitis C drug Olysio helped lift the drug giant’s pharma segment, while medical devices struggled, says Morningstar’s Damien Conover .

  6. Friday Five: What Will the Fed Do Now?

    With inflation still low, a faster rate hike is not a foregone conclusion, says Morningstar markets editor Jeremy Glaser. Plus, one step forward, one step back for Greece, and more.

  7. Obama Pushes to Overhaul Silly, Counterproductive U.S. Corporate Tax System

    The president's proposed tax hikes got all the press, but in an opening bid to Republicans, he also offered to cut the corporate tax rate to 28%.

  8. Obama Pushes to Overhaul Silly, Counterproductive U.S. Corporate Tax System

    The president's proposed tax hikes got all the press, but in an opening bid to Republicans, he also offered to cut the corporate tax rate to 28%.

  9. Johnson & Johnson's Pharma Group Leading the Way

    The firm's consumer and medical-device group are lagging, but strong results from the pharmaceuticals side should drive earnings throughout this year and into 2015, says Morningstar's Damien Conover .

  10. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.